Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 0.81 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18765467 | 0.92 | MAPK1 (0.84) | MAPK1MAPK3 | |
| SCHEMBL18765612 | 0.90 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL18766218 | 0.88 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL18765937 | 0.88 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL18765548 | 0.86 | MAPK1 (0.87) | MAPK1MAPK3 | |
| SCHEMBL18765762 | 0.85 | MAPK1 (0.85) | MAPK1MAPK3 | |
| SCHEMBL18793384 | 0.85 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL30991005 | 0.85 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL18765759 | 0.83 | MAPK1 (0.81) | MAPK1MAPK3 | |
| SCHEMBL20738743 | 0.81 | MAPK1 (0.78) | MAPK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 17/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.